Bazedoxifene acetate is primarily used in the treatment and prevention of osteoporosis in postmenopausal women. It functions as a selective estrogen receptor modulator (SERM), helping to maintain bone density and reduce the risk of fractures. Additionally, it is combined with conjugated estrogens to manage moderate-to-severe vasomotor symptoms associated with menopause and to prevent osteoporosis in women with a uterus. This combination therapy provides the benefits of estrogen while mitigating the risks of endometrial hyperplasia. Its targeted action on bone tissue makes it a valuable option for long-term bone health management in postmenopausal women.